A number of mutant IDH1 inhibitors are currently being evaluated in clinical trials with glioma patients, including AG-120 (Ivosidenib), AG-881 (Vorasidenib), BAY1436032 (Bayer), and DS-1001b (NCT02746081) (162–166). The gene discussed is IDH1; the disease is glioma.